3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Classical hematology
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Plasma cell
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Doxorubicin
25
Radiotherapy
16
apatinib
15
Cyclophosphamide
15
Ifosfamide
13
anlotinib
12
camrelizumab
10
Temozolomide
9
Imatinib Mesylate
9
Vincristine
8
Surgical Procedures, Operative
7
Neoadjuvant Therapy
7
Methotrexate
7
Drug Therapy
7
Dactinomycin
5
Blood Specimen Collection
5
fludarabine phosphate
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
Etoposide
4
Docetaxel
4
Carboplatin
4
toripalimab
3
pembrolizumab
3
Trabectedin
3
Topotecan
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Nivolumab
3
Melphalan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Rivaroxaban
×
Sarcoma
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled